169 Million Birds. Every State. And the Virus Is Still Moving.
The scale of the highly pathogenic avian influenza crisis currently reshaping the U.S. veterinary vaccine landscape is genuinely difficult to absorb in abstract terms. As of May 2025, the Centers for Disease Control and Prevention confirmed that more than 169 million birds had been affected by H5N1 since the outbreak first reached U.S. commercial poultry in February 2022. The virus has been detected in flocks across all 50 states and Puerto Rico. And the crisis has not remained confined to poultry: the USDA’s National Veterinary Services Laboratories confirmed H5N1 in Wisconsin dairy cattle in December 2025, with the National Milk Testing Strategy — a mandatory surveillance programme established in December 2024 — identifying the detection. In 2026, the virus has continued spreading east, with the American Veterinary Medical Association noting a resurgence among commercial poultry driven largely by spillover from migrating wild birds, with spring and fall migrations creating documented seasonal spikes that keep animal health systems on sustained alert.
The Federal Response: $1 Billion, a Grand Challenge, and the Conditional Approval That Matters
The U.S. federal government’s response to HPAI has been the most significant sustained veterinary public health investment in recent memory. The USDA committed $1 billion to the overall HPAI response strategy, encompassing biosecurity support, indemnity payments to affected producers, surveillance infrastructure, and — most consequentially for the vaccine market — research and development funding for next-generation vaccines and rapid diagnostic tools. APHIS committed $100 million specifically to the HPAI Poultry Innovation Grand Challenge, designed to accelerate development of new vaccines and transmission research. On the regulatory side, Zoetis received conditional approval from the USDA Center for Veterinary Biologics in February 2025 for its killed H5N2 virus vaccines, offering cross-protection against H5N1 — a meaningful step forward in the availability of licensed poultry vaccine options in a market where the urgency could not be more clearly demonstrated by the numbers above.
The Cattle Vaccine That Doesn’t Exist Yet — But Might Soon
While poultry vaccines have progressed toward licensure, no licensed vaccine currently exists for H5N1 in U.S. dairy cattle — a gap that is actively being closed through parallel research programmes. Researchers reported in 2026 in the journal Nature Communications on an experimental bovine H5N1 vaccine that produced strong immunity in dairy calves and full protection in mice — results the AVMA characterised as promising. The USDA is simultaneously overseeing field trials of several other bovine vaccine candidates. The detection of the genotype D1.1 strain in Nevada dairy cattle by the National Veterinary Services Laboratory — the first time this genotype, previously identified primarily in wild birds and wild mammals, has been found in dairy cattle — illustrates why the urgency of bovine vaccine development has not diminished. The virus is evolving, and the cattle population represents a reservoir that creates ongoing risk not only for agricultural productivity but for spillover events in the humans who work in and around dairy operations.
Global Vaccine Approvals: A Busy 2026 Pipeline
Beyond the HPAI crisis, the broader global veterinary vaccine regulatory pipeline has been active throughout 2026. Merck Animal Health received approval from China’s agriculture ministry for its live infectious bronchitis vaccine for chickens in May 2026. Hester Biosciences received manufacturing and marketing licences for its inactivated H9N2 avian influenza vaccine for poultry in India in January 2026. Vaksindo Animal Health announced plans in February 2026 to establish a BSL-3 animal vaccine manufacturing facility in Genome Valley, India, targeting poultry, cattle, swine, and aquaculture. Dalan Animal Health, which developed the world’s first honeybee vaccine, reported successful efficacy trials in November 2025 advancing that product toward full USDA licensure. The combination of HPAI urgency, a deepening global pipeline, and expanding vaccination programmes in Asia-Pacific — where Indonesia launched a nationwide livestock vaccination campaign to combat foot-and-mouth disease in January 2026 — together characterise a veterinary vaccine market operating under genuine epidemiological pressure rather than projected demand.
Diagnostic Innovation: Detecting the Virus Before It Reaches the Flock
One of the most practically significant technology developments in 2026’s animal health response has been the emergence of rapid, field-deployable diagnostic tools that enable on-farm H5N1 detection without waiting for laboratory confirmation. The Alveo Sense Poultry Avian Influenza Test, developed by IntelliSense, is a portable molecular test for H5N1 that uses a patented direct electrical sensing method of nucleic acid amplification. The palm-sized analyser allows testing at the point of need — on the farm and in the field — delivering accurate results in approximately 45 minutes via a mobile app. This represents a qualitative shift in outbreak response capability: instead of waiting for samples to be transported to a reference laboratory and results to be returned over one to three days, farm workers and veterinary teams can obtain actionable data within the time window that matters most for biosecurity decision-making. The USDA APHIS continues to invest in expanding surveillance across commercial and backyard birds, wild birds, and dairy cattle through its National Milk Testing Strategy and National Wildlife Disease Programme, underscoring the systemic nature of the federal commitment to early detection.
The Regulatory Architecture: USDA CVB, Conditional Approvals, and the GMP Foundation
The regulatory framework governing U.S. veterinary vaccines sits within the USDA’s Center for Veterinary Biologics, which regulates veterinary vaccines under a rigorous process encompassing laboratory research, clinical trials, and reviews of safety, efficacy, and quality before any product is authorised for market. Manufacturers must adhere to Good Manufacturing Practices that are regularly monitored through inspections. The conditional approval pathway — used for Zoetis’s H5N2 poultry vaccine — provides a faster route to market for vaccines addressing active disease emergencies, with full licensure contingent on the submission of additional efficacy data. This regulatory architecture, while demanding, has historically produced one of the world’s most trusted and scientifically rigorous veterinary biologics portfolios — and its capacity to respond with conditional pathways during genuine outbreaks represents a meaningful tool for addressing animal health crises at the pace those crises actually unfold.
Competitive Landscape and the Path Ahead
The veterinary vaccine competitive landscape in 2026 is being actively shaped by the HPAI outbreak’s investment and regulatory implications. Zoetis and Merck Animal Health remain the two dominant global players, each with significant pipeline investment in avian influenza, companion animal therapeutic vaccines, and livestock biologics. Elanco’s September 2026 FDA approval for an updated label on Zenrelia — removing vaccine-induced disease language — reflects the ongoing regulatory evolution of companion animal therapeutics alongside the livestock vaccine story. The AVMA’s guidance on avian influenza emphasises early reporting of suspected HPAI cases to APHIS and state animal health officials as the foundational biosecurity requirement — underscoring that vaccines, diagnostics, and surveillance form an integrated response system rather than independent product categories. Constancy Researchers’ assessment is that the veterinary vaccines market in 2026 is being driven by genuine, active, and documented epidemiological pressure. The HPAI crisis is not a future scenario around which the market is positioning. It is a present-tense reality that has already cost more than 169 million birds, is actively threatening U.S. dairy cattle, and is generating the most intensive federal veterinary biologics investment in a generation.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
